ISSN 1470-3947 (print) | ISSN 1479-6848 (online)

Endocrine Abstracts (2017) 49 EP984 | DOI: 10.1530/endoabs.49.EP984

Invasive macroprolactinomas and its response to treatment in male patients

Alin Abreu, José Hernández, Margarita Velasco, Pablo Triana & Orlando Castaño

1Centro Medico Imbanaco, Cali, Colombia; 2Instituto Nacional de Endocrinología, La habana, Cuba; 3Universidad Libre Seccional, Cali, Colombia.

Introduction: Prolactin-producing pituitary adenomas are the most common pituitary tumors in clinical practice. In men they are more aggressive and their response to pharmacological treatment is unknown.

Objective: Describe the clinical characteristics and response according to the treatment of a group of male patients with invasive macroprolactinomas.

Materials and methods: A retrospective descriptive study, a series of cases, in 30 patients, attending two pituitary clinics (National Endocrinology Institute in Havana, Cuba and Imbanaco Cali Colombia Medical Center) between 2002 and 2012. Results Between the two types of treatment were compared and measures of central tendency and test of Student or Kruskal Wallis were used.

Results: The mean age was 44±13.8 years; the disease duration was 5.2±4.1 years; 96% of the patients presented headache, followed by hypopituitarism (80%). The median prolactin value at admission was 487 ng/ml. 53% required surgery plus dopaminergic agonists; in this group there was a decrease in prolactin levels of 86% at 6 months and 96% at 12 months; in the dopaminergic agonist group, there was a 71% decrease at 6 months and 95% at 12 months. Surgical patients had the mayor Tumor size reduction 11.4 mm compared with 8.3 mm, however a year there were no difference between the groups.

Conclusion: Surgical treatment plus dopaminergic agonist showed no differences with medical treatment in reducing prolactin values during the first year of treatment regardless of tumor size.

Article tools

My recent searches

No recent searches.